MedTrace Logo

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

NCT04681131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2025-09-25

No results posted yet for this study

Summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

BIOLOGICAL

CAB-AXL-ADC

Conditionally active biologic anti-AXL antibody drug conjugate

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor

Sponsors & Collaborators

  • BioAtla, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2025-07-09
Completion
2025-07-09
FDA Drug
Yes

Countries

  • United States
  • Greece
  • Hong Kong
  • Italy
  • Poland
  • Spain
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04681131 on ClinicalTrials.gov